CRISPR Medicine News and the Chinese Society of Gene & Cell Therapy Announce Media Partnership

COPENHAGEN, Denmark, August 3, 2026 — CRISPR Medicine News (CMN) and the Chinese Society of Gene & Cell Therapy (CSGCT) are pleased to announce a media partnership designed to strengthen international scientific communication and foster greater collaboration across the global CRISPR, gene and cell therapy community.

The partnership brings together a leading independent global media platform dedicated to CRISPR and genomic medicines with China's professional society for gene and cell therapy. Together, CMN and CSGCT will promote scientific exchange through joint content initiatives, expert interviews, trial reports, international roundtable discussions and coverage of major scientific meetings.

As part of the collaboration, CMN will expand its coverage of scientific and clinical developments emerging from China, while CSGCT will facilitate greater visibility of CMN's independently produced content within its professional community. Both organisations will jointly promote their flagship annual events and develop educational activities that strengthen dialogue between researchers, clinicians, innovators and industry across continents.

CMN and CSGCT will co-host a virtual roundtable in early September 2026 to kick off the partnership. Jens-Ole Bock, Founder of CMN, will also chair a session on CRISPR medicine at CSGCT's annual meeting, taking place September 19–20, 2026, in Beijing, China.

Statement from Jens-Ole Bock, Founder, CRISPR Medicine News

“Innovation in gene and cell therapy is increasingly global. Important scientific advances are taking place across many regions of the world, and meaningful progress depends on better communication between them. Through our partnership with CSGCT, we hope to encourage greater international dialogue, share developments from China with a wider audience, and support the exchange of knowledge needed to advance new therapies towards safe and accessible clinical application.At the same time, we remain committed to independent, rigorous reporting on safety and regulatory questions as this field matures - that scrutiny is essential to earning and maintaining public trust.”

Statement from Zhenhua Wu, PhD, President, Chinese Society of Gene & Cell Therapy

“The Chinese Society of Gene & Cell Therapy is pleased to establish this media partnership with CRISPR Medicine News. We look forward to expanding international scientific communication and supporting greater exchange between researchers and clinicians working to advance gene and cell therapies worldwide.”

Looking Ahead

This partnership reflects a shared commitment to advancing international collaboration, improving access to scientific knowledge, and supporting responsible innovation in CRISPR and gene and cell therapy. As these fields continue to evolve at an unprecedented pace, stronger connections between scientific communities will be essential for accelerating research, clinical translation and patient benefit. As the field navigates recent questions around trial safety and transparency, international collaboration on shared standards becomes even more important. This partnership does not extend to editorial content: CMN retains full independence in its reporting, including ongoing coverage of clinical trial safety and regulatory oversight in the field.

About CMN

CRISPR Medicine News (CMN) is the world's leading platform for CRISPR and genomic medicine, with a monthly readership of 35,000 across 170 countries. Since 2018, CMN has tracked CRISPR's journey from groundbreaking research tool to clinical reality, delivering weekly news, expert interviews, webinars and trial updates to its global audience. CMN also convenes the field in person through CRISPRMED, an annual conference launched in 2024 that unites the global CRISPR medicine community to explore the latest advances, ongoing challenges, and emerging solutions in the field. In 2026, CMN expanded its offering with the launch of CMN Intelligence, an extensive open-access database combined with quarterly reports tracking the global landscape of gene-editing trials. At its core, CMN is committed to speeding up the clinical translation of safe gene-editing therapies, helping bring new treatment options to patients worldwide facing rare diseases and complex cancers.

About CSGCT

The Chinese Society of Gene & Cell Therapy (CSGCT) is a leading professional non-profit organisation dedicated to advancing innovation and collaboration in the gene and cell (GCT) field. By connecting scientists, clinicians, regulators, industry leaders, and investors, CSGCT accelerates the translation of breakthrough research into real-world therapies. The society also promotes global integration and expands access to innovative treatments, with the ultimate goal of improving patient outcomes.

Please send inquiries to: press@crisprmedicinenews.com